Page last updated: 2024-09-05

sorafenib and Adenohypophyseal Hyposecretion

sorafenib has been researched along with Adenohypophyseal Hyposecretion in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Akhanlı, P; Bayır, Ö; Çakal, E; Düğer, H; Kertmen, H; Kızılgül, M; Korkmaz, MH; Saylam, G; Sencar, ME; Uçan, B; Yazılıtaş, D; Yılmazer, D1

Other Studies

1 other study(ies) available for sorafenib and Adenohypophyseal Hyposecretion

ArticleYear
Metastatic diffuse follicular variant papillary thyroid cancer without cervical lymph node metastasis presenting with symptoms related to hypopituitarism.
    Einstein (Sao Paulo, Brazil), 2023, Volume: 21

    Topics: Aged; Humans; Hypopituitarism; Iodine Radioisotopes; Lymphatic Metastasis; Male; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy

2023